Liver Disease Treatment Market is estimated to be US$ 33.6 billion by 2032; Rising Prevalence of Liver Diseases Foster the Industrial Growth-By PMI

Prophecy Market Insights latest research report on the Liver Disease Treatment Market provides a comprehensive analysis of the current market scenario, growth opportunities, challenges, and emerging trends. The report offers insights into the market’s size and share, key market players, distribution channels, and consumer preferences. It also examines the impact of the COVID-19 pandemic on the market and provides a detailed analysis of the competitive landscape, including strategic alliances, mergers, and acquisitions.

Covina, Sept. 08, 2023 (GLOBE NEWSWIRE) — INTRODUCTION:

Liver Disease is the condition of liver in patient that stops from working and also prevents it from functioning well. Liver cancer and liver failure result from untreated viral infections and liver illness and thus, can cause liver damage.

Growing geriatric population and prevalence of life-threatening liver problems has become a leading factor in market growth. Rising consumption of alcohol among 18 to 50 age of an individual across globe has become another driving factor in market growth. Further, rising incidence of hepatitis disease across globe due to low quality hygiene and growing population is anticipated to increase demand for Liver Disease Treatment market growth over the forecast period.

Key Highlights:

• In February 2022, Picroliv, a phytopharmaceutical product developed by CDRI (Central Drug Research Institute) has received a permission for phase-III clinical trial in treating fatty liver diseases. New developed “Picroliv” is developed from picrorhiza kurora plant which is also called as Kutki.

Request Free Pdf copy of the report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/1213

Analyst View:

The presence of major players and new advanced treatment with ongoing clinical trials has become a key factor in market growth. Rapid growth in urbanization and adoption of unhealthy lifestyle by an individual such as excess use of alcohol, cigarette smoking has also given rise in liver diseases which has further contributed in Liver Disease Treatment market growth.

Prominent Players in Liver Disease Treatment Market:

• Abbott Laboratories Ltd
• Achillion Pharmaceuticals
• Actavis Pharma Inc
• Alkermes Plc
• Antipodean Pharmaceuticals
• Bayer Healthcare Pharmaceuticals
• Biotest Pharma GmbH
• Bristol-Myers Squibb Company
• Conatus Pharmaceuticals
• Eli Lilly & Company Ltd

Report scope:

Attribute	Details
Base year for estimation	2022
Forecast period	2022 – 2032
Market representation	Revenue in USD Billion & CAGR from 2022 to 2032
Market Segmentation	By Type – Toxic Injury, Infectious Agents & Parasite, Immune Disorders, Tumors, and Inherited Liver Diseases By Application – Hospitals & Specialty, and Clinics
Regional scope	North America – U.S., Canada Europe – UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific – Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America – Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa – South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Download a sample study at for more information on the Liver Disease Treatment Market data from 2022 to 2032:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/1213

Key Drivers:

• Prevalence of Liver Diseases: The increasing incidence of liver diseases, including non-alcoholic fatty liver disease (NAFLD), hepatitis, cirrhosis, and liver cancer, is a major driver. Rising cases of these diseases are driving the demand for effective treatments and therapies.
• Rising Alcohol Consumption: Excessive alcohol consumption remains a leading cause of liver diseases, particularly alcoholic liver disease. The growing consumption of alcohol in some regions contributes to the prevalence of these conditions, thereby driving the need for treatment.
• Hepatitis Epidemics: Outbreaks of hepatitis B and C, both of which can lead to severe liver damage if left untreated, continue to affect populations in various parts of the world. This drives the demand for antiviral treatments and vaccines.
• Non-Alcoholic Fatty Liver Disease (NAFLD): The global obesity epidemic has led to an increase in NAFLD cases, as the condition is closely associated with obesity and metabolic syndrome. The rise in NAFLD cases is spurring research and development efforts for effective treatments.
• Advancements in Medical Technology: Ongoing advancements in medical technology, including imaging techniques and diagnostic tools, have improved the early detection and diagnosis of liver diseases, leading to more timely treatments.

Key Barriers:

• Limited Treatment Options: Many liver diseases, particularly advanced stages of cirrhosis and certain liver cancers, have limited treatment options. This scarcity of effective treatments poses a significant barrier to patients’ well-being.
• High Treatment Costs: The cost of liver disease treatments, including medications, surgeries, and liver transplants, can be prohibitively high. This financial burden can limit access to care, especially for patients without adequate insurance coverage.
• Access to Healthcare: Disparities in healthcare access, both within and between countries, can hinder patients from receiving timely diagnosis and treatment. Inadequate access to healthcare facilities, specialists, and diagnostic tools is a significant barrier.
• Stigma and Awareness: Stigma associated with certain liver diseases, such as viral hepatitis or alcoholic liver disease, can deter individuals from seeking medical help or disclosing their condition. Lack of awareness and education about liver health also contributes to delayed diagnoses.
• Complexity of Liver Transplants: Liver transplantation, while often life-saving, faces challenges related to the availability of donor organs, long waiting lists, and the complexity of the procedure. These factors limit the accessibility of this treatment option.

About Prophecy Market Insights:
Prophecy Market Insights is a leading provider of market research services, offering insightful and actionable reports to clients across various industries. With a team of experienced analysts and researchers, Prophecy Market Insights provides accurate and reliable market intelligence, helping businesses make informed decisions and stay ahead of the competition. The company’s research reports cover a wide range of topics, including industry trends, market size, growth opportunities, competitive landscape, and more. Prophecy Market Insights is committed to delivering high-quality research services that help clients achieve their strategic goals and objectives.

Browse More Related Reports:

1. Immunofluorescence Analyzer Market : Increasing adoption of new technologies and smart solutions with the help of artificial intelligence is the next revolution in patient care that is driving the growth of the market.
2. Molecular Diagnostics Market : By Product (Instruments, Reagents, and Other Products), By Technology (In Situ Hybridization, Chips and Microarrays, Mass Spectrometry (MS), Sequencing, PCR, and Other Technologies), By Application (Infectious Disease, Oncology, Pharmacogenomics, Microbiology, Genetic Disease Screening, Human Leukocyte Antigen Typing, and Blood Screening), By End User (Hospitals, Laboratories, and Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Trends, Analysis and Forecast till 2032
3. Hospital Acquired Disease Testing Market size, share, opportunities, dynamic innovations challenges and forecast 2032.

Blog: www.prophecyjournals.com

Follow us on:

LinkedIn | Twitter | Facebook |YouTube

CONTACT: Shweta R Prophecy Market Insights U.S.: +1 860 531 2574 APAC: +917775049802 Email- sale[email protected] Web: www.prophecymarketinsights.com

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.